A5025628907- Medical Imaging Techniques and Applications
- Radiopharmaceutical Chemistry and Applications
- Advanced Radiotherapy Techniques
- Radiomics and Machine Learning in Medical Imaging
- Particle physics theoretical and experimental studies
- High-Energy Particle Collisions Research
- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Quantum Chromodynamics and Particle Interactions
- Radiation Therapy and Dosimetry
- Lung Cancer Treatments and Mutations
- Neuroblastoma Research and Treatments
- Breast Cancer Treatment Studies
- Advanced X-ray and CT Imaging
- Lung Cancer Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Radiation Dose and Imaging
- Hepatocellular Carcinoma Treatment and Prognosis
- MRI in cancer diagnosis
- Prostate Cancer Treatment and Research
- Particle Detector Development and Performance
- Prostate Cancer Diagnosis and Treatment
- Glioma Diagnosis and Treatment
- Breast Lesions and Carcinomas
- Head and Neck Cancer Studies
European Institute of Oncology
2016-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2008-2025
University of Notre Dame
2023-2024
Ripamonti
2014-2023
Fermi National Accelerator Laboratory
2016-2020
Sapienza University of Rome
2018
University at Buffalo, State University of New York
2016
Fondazione IRCCS Istituto Nazionale dei Tumori
2014
Consejo Nacional de Investigaciones Científicas y Técnicas
2014
Ferrari (Italy)
2014
Peptide receptor radionuclide therapy (PRRNT) is a molecularly targeted radiation involving the systemic administration of radiolabelled peptide designed to target with high affinity and specificity receptors overexpressed on tumours. PRRNT employing radiotagged somatostatin agonists 90Y-DOTATOC ([90Y-DOTA0,Tyr3]-octreotide) or 177Lu-DOTATATE ([177Lu-DOTA0,Tyr3,Thr8]-octreotide [177Lu-DOTA0,Tyr3]-octreotate) have been successfully used for past 15 years metastatic inoperable neuroendocrine...
The purpose of the EANM Dosimetry Committee is to provide recommendations and guidance scientists clinicians on patient-specific dosimetry. Radiopharmaceuticals labelled with lutetium-177 (177Lu) are increasingly used for therapeutic applications, in particular treatment metastatic neuroendocrine tumours using ligands somatostatin receptors prostate adenocarcinoma small-molecule PSMA-targeting ligands. This paper provides an overview reported dosimetry data these therapies summarises current...
Primary liver tumours (i.e. hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC)) are among the most frequent cancers worldwide. However, only 10-20% of patients amenable to curative treatment, such as resection transplant. Liver metastases frequently caused by colorectal cancer, which accounts for second cancer-related deaths in Europe. In both primary and secondary tumours, radioembolization has been shown be a safe effective treatment option. The vast potential...
Renal toxicity associated with small-molecule radionuclide therapy has been shown to be dose-limiting for many clinical studies. Strategies maximizing dose the target tissues while sparing normal critical organs based on absorbed and biologic response parameters are commonly used in external-beam therapy. However, radiopharmaceuticals passing though kidneys result a differential rate suborgan elements, presenting significant challenge assessing an accurate dose–response relationship that is...
The increasing availability of SPECT/CT devices with advanced technology offers the opportunity for accurate assessment radiation dose to biological target volume during radionuclide therapy. Voxel dosimetry can be performed employing direct Monte Carlo transport simulations, based on both morphological and functional images patient. On other hand, voxel calculations S value method considered an easier approach than patient-specific ensuring a good dosimetric accuracy at least anatomic...
Abstract The numbers of diagnostic and therapeutic nuclear medicine agents under investigation are rapidly increasing. Both novel emitters carrier molecules require careful selection measurement procedures. This document provides guidance relevant to dosimetry for first-in human early phase clinical trials such agents. guideline includes a short introduction different molecules, followed by recommendations on the methods activity measurement, pharmacokinetic analyses, as well absorbed dose...
This substudy of the phase III NETTER-1 trial evaluated [<sup>177</sup>Lu]Lu-DOTATATE (hereafter <sup>177</sup>Lu-DOTATATE) for advanced midgut neuroendocrine tumors and aimed to assess dosimetry a standard 4-cycle protocol any potential relationship toxicity. Change in tumor size by absorbed dose was an exploratory endpoint. <b>Methods:</b> Patients with locally or metastatic, well-differentiated, were enrolled this between August 2013 January 2016. scheduled receive 4 infusions 7.4 GBq...
Lymph node pathologic status is the most important prognostic factor in vulvar cancer; however, complete inguinofemoral dissection associated with significant morbidity. Lymphoscintigraphy gamma-probe guided surgery reliably detects sentinel nodes melanoma and breast cancer patients. This study evaluates feasibility of surgical identification groin using lymphoscintigraphy a gamma-detecting probe patients early cancer. Technetium-99m-labelled colloid human albumin was administered...